PDL BioPharma Product Sales Up 25 Percent On Cardene Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.
You may also be interested in...
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
PDL BioPharma Plans To Divest Assets, Emerge As Pure Play Biotech
Sale of PDL’s lucrative royalty stream or even the company itself is not off the table as reorganization unfolds.